

# PHARMACY FACTS

## Program Updates from Louisiana Medicaid

*February 15, 2019*

### **UnitedHealthcare brand drug reimbursement**

On February 10, 2019, UnitedHealthcare (BIN 610494, PCN 9999, Group ACULA), one of the five managed care organizations (MCOs) contracted with Medicaid for service delivery, updated an average acquisition cost (AAC) file. This resulted in some issues with the reimbursement on ingredient cost on some brand name drugs. The file was corrected on February 12, 2019.

UnitedHealthcare will be reaching out by telephone to impacted pharmacies so that claims can be reprocessed for updated reimbursement. If you have questions please call the UnitedHealthcare Pharmacy Director, Travis Ortiz, at (504) 849-1546.

### **Generic Tamiflu rate**

The Louisiana Department of Health (LDH) was made aware of an AAC rate issue for oseltamivir (generic Tamiflu) suspension. Myers and Stauffer reviewed and updated the rate retrospectively to January 25, 2019. The new rate was sent to the MCOs in this week's file on February 14, 2019. The MCOs have seven days to program new rates, clearing the way for claims to be reprocessed on February 22, 2019 for the updated rate.

### **Single preferred drug list update**

LDH and the MCOs are currently coding drug files and working with programmers to implement the single preferred drug list (PDL) on May 1, 2019. The single PDL is the product of a collaborative administrative simplification effort for both prescribers and pharmacists who provide care to Medicaid members.

The single PDL will align all preferred drugs across fee-for-service Medicaid and the five MCOs. The list of drugs that require prior authorization will also be consistent. In preparation of the transition to a single PDL, notifications will be sent on March 1 to recipients and providers if the single PDL will cause a current preferred medication to require a prior authorization after May 1.